The high-profile biotech is zeroing in on programs that serve as proof points for its technology, while seeking partners for other assets.

On Friday, Bristol-Myers Squibb Co (BMY) stock saw a modest uptick, ending the day at $50.91 which represents a slight increase of $0.79 or 1.58% from the prior close of $50.12. The stock opened at ...

MM+M’s 2024 Healthcare Marketers Trend Report reveals that AI and tech are top of mind for healthcare marketers. In this recent #TrendTalks session titled “The Ideal Customer Experience Across the ...

After putting on a strong performance in preventing disease progression in the earlier treatment of multiple myeloma, Johnson ...

RA Capital, RTW Investments, Janus Henderson Investors are pouring another $175 million into a radiopharmaceuticals startup.

Prime Medicine said it will receive a $55 million upfront payment and a $55 million investment from Bristol Myers Squibb. It will is also eligible to receive more than $3.5 billion in milestones, ...

In a 3-year extension of the pivotal trials that provided lebrikizumab with an indication for atopic dermatitis, the response ...

Prime Medicine, founded by David Liu, is finding that the path of translating scientific breakthroughs to treatments is ...

One upcoming decision—on a perioperative PD-1 regimen for lung cancer—comes as the FDA considers an overhaul of trial designs in this treatment setting.

Adding daratumumab to lenalidomide in maintenance therapy for multiple myeloma significantly reduced rates of minimal ...

ASX could hit record high despite mixed bag on Wall Street. US stocks expected to outperform bonds as Fed cuts rates.